Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells

Dae Suk Kim, Dong Hyun Kim, Boncheol Goo, Young Hun Cho, Jin Mo Park, Tae Hyung Lee, Hyun Ok Kim, Han Soo Kim, Hyunah Lee, Jong Doo Lee, Dashlkhumbe Byamba, Jeong Hwan Je, Mingeol Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10 7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.

Original languageEnglish
Pages (from-to)990-998
Number of pages9
JournalYonsei medical journal
Volume52
Issue number6
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Immunotherapy
Dendritic Cells
Monocytes
Melanoma
Vaccination
Neoplasm Antigens
Neoplasms
Immunosorbents
Delayed Hypersensitivity
Korea
Tumor Burden
Disease Progression
Blood Cells
Cytokines
Safety
Antigens
Enzymes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Dae Suk ; Kim, Dong Hyun ; Goo, Boncheol ; Cho, Young Hun ; Park, Jin Mo ; Lee, Tae Hyung ; Kim, Hyun Ok ; Kim, Han Soo ; Lee, Hyunah ; Lee, Jong Doo ; Byamba, Dashlkhumbe ; Je, Jeong Hwan ; Lee, Mingeol. / Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. In: Yonsei medical journal. 2011 ; Vol. 52, No. 6. pp. 990-998.
@article{3249eab846cb47249468a7473f8c2c6c,
title = "Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells",
abstract = "Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10 7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.",
author = "Kim, {Dae Suk} and Kim, {Dong Hyun} and Boncheol Goo and Cho, {Young Hun} and Park, {Jin Mo} and Lee, {Tae Hyung} and Kim, {Hyun Ok} and Kim, {Han Soo} and Hyunah Lee and Lee, {Jong Doo} and Dashlkhumbe Byamba and Je, {Jeong Hwan} and Mingeol Lee",
year = "2011",
month = "11",
day = "1",
doi = "10.3349/ymj.2011.52.6.990",
language = "English",
volume = "52",
pages = "990--998",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

Kim, DS, Kim, DH, Goo, B, Cho, YH, Park, JM, Lee, TH, Kim, HO, Kim, HS, Lee, H, Lee, JD, Byamba, D, Je, JH & Lee, M 2011, 'Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells', Yonsei medical journal, vol. 52, no. 6, pp. 990-998. https://doi.org/10.3349/ymj.2011.52.6.990

Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells. / Kim, Dae Suk; Kim, Dong Hyun; Goo, Boncheol; Cho, Young Hun; Park, Jin Mo; Lee, Tae Hyung; Kim, Hyun Ok; Kim, Han Soo; Lee, Hyunah; Lee, Jong Doo; Byamba, Dashlkhumbe; Je, Jeong Hwan; Lee, Mingeol.

In: Yonsei medical journal, Vol. 52, No. 6, 01.11.2011, p. 990-998.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells

AU - Kim, Dae Suk

AU - Kim, Dong Hyun

AU - Goo, Boncheol

AU - Cho, Young Hun

AU - Park, Jin Mo

AU - Lee, Tae Hyung

AU - Kim, Hyun Ok

AU - Kim, Han Soo

AU - Lee, Hyunah

AU - Lee, Jong Doo

AU - Byamba, Dashlkhumbe

AU - Je, Jeong Hwan

AU - Lee, Mingeol

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10 7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.

AB - Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10 7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=80055006690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055006690&partnerID=8YFLogxK

U2 - 10.3349/ymj.2011.52.6.990

DO - 10.3349/ymj.2011.52.6.990

M3 - Article

VL - 52

SP - 990

EP - 998

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -